Market Closed - Nyse 04:00:02 2024-07-18 pm EDT 5-day change 1st Jan Change
41.78 USD -1.65% Intraday chart for Qiagen N.V. +1.63% -6.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT MT
Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans CI
Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50 MT
Qiagen Seeks M&A CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call
Sartorius on the downswing again - low since 2020 is approaching DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating MT
QIAGEN NV : Gets a Neutral rating from UBS ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating ZD
QIAGEN NV : Berenberg remains its Buy rating ZD
Frankfurt shares close: Dax recovers DP
Transcript : Qiagen N.V. - Analyst/Investor Day
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15 DP
Qiagen Targets 7% Annual Sales Growth Through 2028 MT
Qiagen eyes sales growth of 7% per year until 2028 RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024 CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test MT
Chart Qiagen N.V.
More charts
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
41.78 USD
Average target price
49.73 USD
Spread / Average Target
+19.03%
Consensus
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. News Qiagen N.V.
  5. Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test